Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
xTacX8YhhUgr4pmp
Listen
Français